ANI Pharmaceuticals (NASDAQ:ANIP – Free Report) had its price objective raised by Guggenheim from $59.00 to $62.00 in a research note issued to investors on Thursday morning, FlyOnTheWall reports. Other equities research analysts also recently issued research reports about the company. Truist Financial upped their target price on ANI Pharmaceuticals from $52.00 to $60.00 and […]
ANI Pharmaceuticals (NASDAQ:ANIP – Free Report) had its price target raised by Truist Financial from $52.00 to $60.00 in a research note released on Friday morning, Marketbeat.com reports. They currently have a buy rating on the specialty pharmaceutical company’s stock. Several other research firms also recently weighed in on ANIP. StockNews.com downgraded shares of ANI […]
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) COO Muthusamy Shanmugam sold 5,969 shares of the business’s stock in a transaction that occurred on Wednesday, July 19th. The stock was sold at an average price of $51.48, for a total transaction of $307,284.12. Following the sale, the chief operating officer now owns 1,250,120 shares of […]
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) COO Muthusamy Shanmugam sold 10,000 shares of the company’s stock in a transaction dated Friday, July 14th. The shares were sold at an average price of $50.43, for a total transaction of $504,300.00. Following the transaction, the chief operating officer now directly owns 1,272,620 shares of the […]
StockNews.com cut shares of ANI Pharmaceuticals (NASDAQ:ANIP – Get Rating) from a buy rating to a hold rating in a research report sent to investors on Tuesday. A number of other equities analysts have also weighed in on ANIP. HC Wainwright increased their target price on ANI Pharmaceuticals from $53.00 to $60.00 in a research […]